caa a22 4500 397593058 CHVBK 20180308164944.0 cr unu---uuuuu 161202e199606 xx s 000 0 eng 10.1093/jac/37.suppl_C.103 doi (NATIONALLICENCE)oxford-10.1093/jac/37.suppl_C.103 Zachariah J. ICON Clinical Research Ltd, Dundrum Castle, Ballinteer Road, Dublin, Ireland A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections [Elektronische Daten] [J. Zachariah] Clinical and bacteriological efficacy and tolerability of azithromycin (500 mg once daily for 3 days) and those of a 10-day regimen of co-amoxiclav (37 mg three times daily) were evaluated in a large-scale, double-blind comparative study of 369 patients (≥18 years old) with acute lower respiratory tract infections. After treatment, 165/173 (95%) azithromycin- and 166/173 (96%) co-amoxiclav-treated patients had responded satisfactorily (cure or improvement). Baseline pathogens (mainly Streptococcus pneumoniae and Haemophilus influenzae) were eradicated in 82/82 (100%) azithromycin- and 73/74 (99%) co-amoxiclav-treated patients who were bacteriologically assessable. Adverse events, which were predominantly of mild to moderate severity and mostly affected the gastrointestinal system, were recorded in 13/186 (7%) azithromycin- and 19/183 (10%) co-amoxiclav-treated patients. Only two (1 %) azithromycin-treated patients discontinued treatment due to adverse events compared with eight (4%) who received co-amoxiclav. The results show that azithromycin at a dose of 500 mg once daily for 3 days is an effective and safe alternative to a 10-day, three-times-daily course of co-amoxiclav in the treatment of lower respiratory tract infections in adults. © 1996 The British Society for Antimicrobial Chemotherapy Articles nationallicence Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-06), 103-113 0305-7453 37<103 1996 37 jac https://doi.org/10.1093/jac/37.suppl_C.103 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.suppl_C.103 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Zachariah J. ICON Clinical Research Ltd, Dundrum Castle, Ballinteer Road, Dublin, Ireland NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-06), 103-113 0305-7453 37<103 1996 37 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford